As a next generation pharmaceutical company, to say things change fast around here is an understatement. Whether it’s robust results from one of our clinical trials or a newfound strategic partnership that has inspiring possibilities, new developments abound. And since keeping our stake holders informed is a priority, we’ll keep you up-to-date with news and exciting breakthroughs.

News

DATE

TITLE

August 16, 2011 POZEN Welcomes Clint Burrus as Vice President, Customer Development Printer Friendly Version
August 08, 2011 Pozen Patents Upheld in Treximet Patent Litigation Printer Friendly Version
July 28, 2011 POZEN Reports Second Quarter 2011 Results Printer Friendly Version
July 27, 2011 POZEN Welcomes Dr. Seth A. Rudnick to the Board of Directors Printer Friendly Version
July 19, 2011 POZEN Forms Unprecedented Advisory Board of Digital Thought-Leaders to Advance Commercial Plans Printer Friendly Version
July 14, 2011 POZEN Announces July 28, 2011 Webcast of Second Quarter 2011 Results Printer Friendly Version
June 16, 2011 POZEN Announces Election of Dr. Martin Nicklasson to the Board of Directors Printer Friendly Version
June 15, 2011 POZEN to Present at The UBS Specialty Pharmaceuticals Conference Printer Friendly Version
June 09, 2011 POZEN to Present at the 2011 Wells Fargo Securities Healthcare Conference Printer Friendly Version
May 25, 2011 POZEN Ranked as Second Most Efficient Pharma Company by SmarTrend Printer Friendly Version
May 24, 2011 POZEN to Present at the Jefferies 2011 Global Life Sciences Conference Printer Friendly Version
May 05, 2011 POZEN Reports First Quarter 2011 Results Printer Friendly Version
April 25, 2011 AstraZeneca and POZEN File Patent Infringement Lawsuit Against Dr. Reddy’s Printer Friendly Version
April 21, 2011 POZEN Announces May 5, 2011 Webcast of First Quarter 2011 Results Printer Friendly Version
April 15, 2011 Preliminary Injunction Ordered in POZEN Treximet Patent Litigation Printer Friendly Version
March 24, 2011 POZEN To Present at the 10th Annual Needham Healthcare Conference Printer Friendly Version
March 24, 2011 POZEN Reports Superior Platelet Inhibition of PA32540 Regimen Over a Standard of Care Regimen in a Phase 1 Study (“Co-Rx”) Printer Friendly Version
March 23, 2011 POZEN Announces Licensing Deal with Cilag GmbH, A Division of Johnson & Johnson, for MT 400, Migraine Treatment Printer Friendly Version
March 22, 2011 POZEN Files Motion for Preliminary Injunction in Treximet Patent Litigation Printer Friendly Version
March 09, 2011 POZEN Reports Fourth Quarter and Year End 2010 Results Printer Friendly Version
February 24, 2011 POZEN Announces March 9, 2011 Webcast of Fourth Quarter & Year End 2010 Results Printer Friendly Version
February 23, 2011 POZEN to Present at the Cowen and Company 31st Annual Healthcare Conference Printer Friendly Version
February 22, 2011 POZEN Announces Addition to Commercial Team Printer Friendly Version